FIG. 2.

Efficacy of delayed therapy against disseminated C. albicans MY1055 infection in CY-treated, transient-suppression model in ICR mice. Mice were challenged i.v. with C. albicans MY1055 at 2.0 × 10⁴ CFU/mouse. Mice (10/group) received first treatment 24 h after challenge (delayed therapy) and were treated i.p., q.d., for 7 days. Mice were immunosuppressed with a 6-mg/mouse dose of CY on day −3. Immunosuppression was maintained by additional doses of CY on days 1 and 4 after challenge. (A) Caspofungin; (B) AmB.